Homepage
About Us
About Kybora
Leadership Team
Success Stories
Our Global Presence
Social Responsibility
Services
M&A
Licensing
Fundraising
Strategic Advisory
News Feed
Contact
English
English
中文
Homepage
About Us
About Kybora
Leadership Team
Success Stories
Our Global Presence
Social Responsibility
Services
M&A
Licensing
Fundraising
Strategic Advisory
News Feed
Contact
English
English
中文
KYBORA and ACA Pharma Partner to Accelerate Access to China’s Life Sciences Market
October 8, 2025
News
Strategic collaboration combines KYBORA’s global biopharma network with ACA Pharma’s 30–90 day Macau registration model to expedite access for rare disease and pediatric therapies in China. KYBORA and ACA Pharma…
READ MORE
KYBORA is pleased to announce that Wang Zhi has joined its team at EVP and Managing Director of its Asia Pac operations.
June 21, 2023
News
SHANGHAI AND PRINCETON, N.J. JUNE 09, 2023KYBORA Life Sciences, a global advisory firm dedicated to facilitating enduring success for life…
READ MORE
Q1 2023 Global Biopharma Market Trends and News
April 12, 2023
News
In this report (download here) , Q1 2023 Global Biopharma Market Trends and News, we cover the key Biotech/Pharma trends…
READ MORE
KYBORA is happy to announce that Khai Meng Ang has joined its team as Senior Advisor for China.
February 6, 2023
News
KYBORA's mission is to help life science companies achieve enduring success. Khai's addition to our team allows us to provide…
READ MORE
KYBORA announces that Megalabs has acquired acquired Fr!ska
February 3, 2023
Mergers and Acquisitions, News
KYBORA is pleased to announce that its client Megalabs has acquired acquired Fr!ska.
READ MORE
KYBORA is pleased to announce the licensing of Daewoong’s development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China region.
February 3, 2023
Global Licensing, News
KYBORA is pleased to announce the licensing of Daewoong's development stage IPF therapy (Bersiporocin) to CS Pharmaceuticals for the Greater China…
READ MORE
KYBORA is pleased to announce that its trademarks have been approved and registered by the Chinese government.
June 24, 2022
News
KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People's Republic of China.
READ MORE
KYBORA is pleased to announce the partnering of ORLADEYO® (berotralstat) in Latin America.
June 14, 2022
Global Licensing, News
KYBORA is please to announce that its client Pint Pharma has completed an agreement to commercialize Orladeyo in Latin America
READ MORE
KYBORA is pleased to announce the licensing of Accure Therapeutics ACT-01 to Oculis.
March 2, 2022
Global Licensing
KYBORA is pleased to announce the global licensing of ACT-01 from Accure Therapeutics to Oculis. This transaction further demonstrates KYBORA's…
READ MORE
KYBORA Welcomes Howard Lei To its Team
December 22, 2021
News
Princeton, NJ – October 12th, 2021 KYBORA is pleased to announce that Howard Lei (MBA, MS-IT, PMP) has joined its…
READ MORE
KYBORA Welcomes Leonid Parshenkov To The Team
September 21, 2021
News
KYBORA is pleased to announce that Dr. Leonid Parshenkov, MD has joined its team as Senior Advisor, responsible for expanding…
READ MORE
BGx: Trends and Strategic Options
August 30, 2021
News
Download full presentation here
READ MORE
Jean Chatellier in “Ask the Experts” Interview Series by Sejelas
July 2, 2021
News
Recently, KYBORA Managing Director Jean Chatellier had an opportunity to share insights with industry leader Sejelas’ Ask the Experts Interview…
READ MORE
«
‹
5
6
7
8
9
›
»
TYPE & ENTER:
Close
